- Company's first bioink available in powder form provides
enhanced operational flexibility to support a wide range of 3D
bioprinting applications
- Collink.3D™ 50L strengthens CollPlant's platform of
bioink solutions to biopharma and academic customers seeking
animal-free alternatives with improved bio-functionality, safety
and reproducibility
REHOVOT, Israel, Jan. 3, 2023
/PRNewswire/ -- CollPlant (Nasdaq: CLGN), a
regenerative and aesthetics medicine company developing innovative
human collagen-based technologies and products for tissue
regeneration and organ manufacturing, today announced the launch of
Collink.3DTM 50L, a recombinant human collagen
(rhCollagen)-based bioink in a powder form for use in a wide range
of 3D bioprinting applications, including drug discovery, drug
screening, tissue testing as well as the development of
transplantable tissues and organs.
Collink.3DTM 50L, the result of a comprehensive
development effort, is a tunable bioink that can be easily
reconstituted to form solutions with application-specific
concentrations, formulated with other components and crosslinked to
form hydrogels that meet the demand for specific geometric,
physical and biological properties of different 3D constructs.
Collink.3D™ 50L adds to CollPlant's growing portfolio of commercial
bioinks launched over the last year, Collink.3DTM 50 and
Collink.3DTM 90.
"We continue to innovate and support the biopharma and academia
with their 3D bioprinting applications by offering a commercial
bioink in powder form that improves operational flexibility,
including more convenient shipment, handling and storage of the
product," said CollPlant CEO, Yehiel
Tal. "Much like our other bioinks,
Collink.3DTM 50L provides a state-of-the-art animal-free
alternative to existing commercial bioinks, enabling
high-resolution, scalable and reproduceable bioprinting of
scaffolds that accurately mimic the physical properties of human
tissues and organs. Our bioink platform is intended to enable our
customers to streamline the process of new product development
while also accelerating timelines and reducing overall costs,"
added Tal.
Biofabricated constructs composed of Collink.3DTM
offer superior biological performance, consistency and safety.
The Collink.3D™ platform is compatible with major
3D bioprinting technologies and cell types.
More information can be found
on https://bit.ly/3YTUVvN
Contact us for more details collink.3d@collplant.com
About CollPlant
CollPlant is a regenerative and aesthetic medicine company
focused on 3D bioprinting of tissues and organs, and medical
aesthetics. The Company's products are based on its rhCollagen
(recombinant human collagen) produced with CollPlant's proprietary
plant based genetic engineering technology. These products address
indications for the diverse fields of tissue repair, aesthetics,
and organ manufacturing, and are ushering in a new era in
regenerative and aesthetic medicine.
In 2021 CollPlant entered into a development and global
commercialization agreement for dermal and soft tissue fillers with
Allergan, an AbbVie company, the global leader in the dermal filler
market. For more information about CollPlant, visit
http://www.collplant.com
Safe Harbor Statements
This press release may include forward-looking statements.
Forward-looking statements may include, but are not limited to,
statements relating to CollPlant's objectives plans and strategies,
as well as statements, other than historical facts, that address
activities, events or developments that CollPlant intends, expects,
projects, believes or anticipates will or may occur in the future.
These statements are often characterized by terminology such as
"believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Many factors could cause CollPlant's actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to, the following: the Company's history of significant
losses, its ability to continue as a going concern, and its need to
raise additional capital and its inability to obtain additional
capital on acceptable terms, or at all; the impact of the COVID-19
pandemic; the Company's expectations regarding the timing and cost
of commencing clinical trials with respect to tissues and organs
which are based on its rhCollagen based BioInk and products for
medical aesthetics; the Company's ability to obtain favorable
pre-clinical and clinical trial results; regulatory action with
respect to rhCollagen based BioInk and medical aesthetics products
including but not limited to acceptance of an application for
marketing authorization review and approval of such application,
and, if approved, the scope of the approved indication and
labeling; commercial success and market acceptance of the Company's
rhCollagen based products in 3D Bioprinting and medical aesthetics;
the Company's ability to establish sales and marketing capabilities
or enter into agreements with third parties and its reliance on
third party distributors and resellers; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the Company's reliance on third parties to conduct
some or all aspects of its product manufacturing; the scope of
protection the Company is able to establish and maintain for
intellectual property rights and the Company's ability to operate
its business without infringing the intellectual property rights of
others; the overall global economic environment; the impact of
competition and new technologies; general market, political, and
economic conditions in the countries in which the Company operates;
projected capital expenditures and liquidity; changes in the
Company's strategy; and litigation and regulatory proceedings. More
detailed information about the risks and uncertainties affecting
CollPlant is contained under the heading "Risk Factors" included in
CollPlant's most recent annual report on Form 20-F filed with the
SEC, and in other filings that CollPlant has made and may make with
the SEC in the future. The forward-looking statements contained in
this press release are made as of the date of this press release
and reflect CollPlant's current views with respect to future
events, and CollPlant does not undertake and specifically disclaims
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact at CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Email: Eran@CollPlant.com
Photo
- https://mma.prnewswire.com/media/1976093/Collink_3D_50L.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/collplant-enriches-portfolio-of-rhcollagen-based-bioinks-with-launch-of-collink3dtm-50l-in-powder-form-301712219.html
SOURCE CollPlant